Contraline, a biotechnology company, has secured an exclusive licensing agreement with the Population Council for NES/T Gel, an investigational male contraceptive. This partnership positions Contraline as a leader in developing and commercializing male contraceptives globally.
NES/T Gel is a transdermal, reversible hormonal contraceptive that uses Nestorone and testosterone to suppress sperm production. Preliminary clinical trials have shown promising results, with over 750 men participating and suggesting high effectiveness with manageable side effects.
Contraline now boasts a pipeline of two male contraceptives: NES/T Gel and ADAM, an implantable device. These products aim to provide reliable and reversible options for men, who currently have limited choices beyond condoms and vasectomy.
The global demand for male contraceptives is substantial, with estimates suggesting that millions of men would welcome novel methods. Contraline’s mission aligns with this need, as the company strives to transform global contraceptive solutions and promote reproductive equality.
Currently, NES/T Gel is completing a Phase 2b trial assessing its efficacy and safety. Upon exercising the option and meeting with the FDA, Contraline plans to initiate a Phase 3 program, marking a significant advancement in the field.
Contraline’s partnership with the Population Council and NICHD underscores its commitment to developing innovative solutions that empower men with choice and control over their reproductive health.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
